News

Predicting universal anti-influenza drugs

Predicting universal anti-influenza drugs

University of Hertfordshire researchers have developed a new concept which could lead to the discovery of universal anti-influenza drugs. It is hoped that this new way of including more than 12,000 influenza virus gene sequences will ensure that predicted antivirals are effective against most influenza virus strains. The findings were published recently in the journal Virology.

Features

Coverslipping for high-quality immunohistochemistry: an automated experience

Coverslipping for high-quality immunohistochemistry: an automated experience

Quality, convenience and timely support when needed are some of the reasons why staff in histopathology at Bath are reaping the benefits of automated ClearVue coverslipping from Thermo Scientific.

Closing critical gaps in tackling the ongoing  threat of tuberculosis

Closing critical gaps in tackling the ongoing threat of tuberculosis

The World Health Organization is calling for increased efforts and investment to end one of the world’s oldest and deadliest diseases. But have we become complacent about the threat posed by TB in the UK? Are healthcare workers prepared for outbreaks, and what are they doing to protect themselves and their patients? Louise Frampton reports.

Upcoming Events

Microscience Microscopy Congress 2017 (mmc2017)

Manchester
3-6 July 2017

Pathology Horizons CPD conference

Paradise Palms, Cairns, Australia
10th-12th August

UK NEQAS for Blood Coagulation: Providing an Anticoagulant Service

The Principal York Hotel, Station Road, York YO24 1AA
22 September 2017

IBMS Biomedical Science Congress

ICC, Birmingham
24-27 September 2017

UK NEQAS: Coordinating Point-of-Care Testing

Queen Elizabeth II Conference Centre, Broad Sanctuary, Westminster, London SW1 3EE
20 October 2017

Latest Issue

Pathology In Practice

Pathology In Practice

May 2017

Slides for success in tissue adhesion

Register now to apply for regular copies of Pathology In Practice and free access to premium content, as well as our regular newsletters.